HIGHLIGHTS
SUMMARY
Chimeric antigen receptor (CAR) T_cells therapies are one of the most exciting developments in recent cancer immunotherapies. CAR-T_cells act as engineered immune cells that track down a targeted antigen, then induce apoptosis on the cells bearing the targeted antigen. Current research are also focusing on implementing CAR constructs on other immune cells such as macrophages and improving the safety profile of current CAR-T_cells. When scFv of CARs binds to the antigen CD19, the CAR T_cells are activated with the amplified activation signals in a cascade manner to proliferate and kill the tumour . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.